Pavel Kapysh / Shutterstock.com
Amarin is seeking a certiorari review of a previous judgement by the Federal Circuit that denied the company the right to renew six patents relating to Vascepa—Amarin’s sole product.
The company claimed in a petition that the Federal Circuit’s ruling to deny the revival resulted in an “over-invalidation of patents through hindsight bias and the suppression of innovation”.
“The Federal Circuit’s refusal to correct its error will broadly invalidate patents on inventions whose validity is established by real-world evidence of ingenuity simply because that evidence is ignored until the court has already formed an opinion of ‘prima facie’ obviousness,” said the Dublin-based company.
The six patents were initially set to expire in 2029.
In response to the Nevada Court’s decision, Amarin sought an appeal from the US Court of Appeals for the Federal Circuit, which was heard in September 2020. The Federal Circuit decided to uphold the Nevada Court’s decision and not revive the patents.
“We are extremely disappointed with today’s ruling and plan to vigorously pursue available remedies,” said John Thero, president and chief executive officer, Amarin in response to the judgment.
“Importantly, we and our partners are continuing to pursue additional regulatory approvals for Vascepa in China, Europe and the additional countries in the Middle East, and remain confident in the global market potential of Vascepa.”
In a complaint filed at the US District Court of Delaware on November 30, 2020, Amarin claimed Hikma is infringing its Vascepa patents and sought a jury trial.
Did you enjoy reading this story? Sign up to our free daily newsletters and get stories sent like this straight to your inbox
Amarin, Vascepa, Supreme Court, big pharma, patents